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Polyunsaturated fatty acid receptors, GPR40
and GPR120, are expressed in the
hypothalamus and control energy
homeostasis and inflammation
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Elisabeth Christiansen2, Carlos Azevedo2, Trond Ulven2 and Licio A. Velloso1,3*
Abstract
Background: The consumption of large amounts of dietary fats is one of the most important environmental factors
contributing to the development of obesity and metabolic disorders. GPR120 and GPR40 are polyunsaturated fatty
acid receptors that exert a number of systemic effects that are beneficial for metabolic and inflammatory diseases.
Here, we evaluate the expression and potential role of hypothalamic GPR120 and GPR40 as targets for the
treatment of obesity.
Methods: Male Swiss (6-weeks old), were fed with a high fat diet (HFD, 60% of kcal from fat) for 4 weeks. Next,
mice underwent stereotaxic surgery to place an indwelling cannula into the right lateral ventricle.
intracerebroventricular (icv)-cannulated mice were treated twice a day for 6 days with 2.0 μL saline or GPR40 and
GPR120 agonists: GW9508, TUG1197, or TUG905 (2.0 μL, 1.0 mM). Food intake and body mass were measured
during the treatment period. At the end of the experiment, the hypothalamus was collected for real-time PCR
analysis.
Results: We show that both receptors are expressed in the hypothalamus; GPR120 is primarily present in microglia,
whereas GPR40 is expressed in neurons. Upon intracerebroventricular treatment, GW9508, a non-specific agonist for
both receptors, reduced energy efficiency and the expression of inflammatory genes in the hypothalamus. Reducing
GPR120 hypothalamic expression using a lentivirus-based approach resulted in the loss of the anti-inflammatory effect
of GW9508 and increased energy efficiency. Intracerebroventricular treatment with the GPR120- and GPR40-specific
agonists TUG1197 and TUG905, respectively, resulted in milder effects than those produced by GW9508.
Conclusions: GPR120 and GPR40 act in concert in the hypothalamus to reduce energy efficiency and regulate the
inflammation associated with obesity. The combined activation of both receptors in the hypothalamus results in better
metabolic outcomes than the isolated activation of either receptor alone.
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Background
The consumption of large amounts of dietary fats is one
of the most important environmental factors contribut-
ing to the development of obesity and metabolic disor-
ders [1–3]. Long-chain saturated fatty acids trigger
inflammation through the activation of toll-like
receptor-4 and the induction of endoplasmic reticulum
stress [4–6]. The low-intensity inflammation generated
in this context can act both systemically and on selected
anatomical regions to affect insulin and leptin actions
[7], insulin production [8, 9], lipid metabolism [10],
blood pressure [11], longevity [12], and a number of
other parameters involved in the regulation of whole-
body energy homeostasis.
Because of the role played by metabolic inflammation
in the pathogenesis of insulin and leptin resistance, it
has been proposed that approaches leading to the at-
tenuation of inflammation could have a beneficial impact
on conditions such as obesity, type 2 diabetes, dyslipid-
emia, and hypertension [13–15]. In fact, genetic and
pharmacological approaches aimed at reducing inflam-
mation have produced encouraging outcomes in various
experimental models [9, 14]. In addition, a recent clinical
trial targeted the inhibitor of kappa kinase (IKK) using
salsalate, resulting in a significant reduction of glycated
hemoglobin levels in patients with type 2 diabetes [16].
Studies have identified the polyunsaturated fatty acid
(PUFA) receptors GPR120 and GPR40 as attractive po-
tential targets for the treatment of insulin resistance
[17–20]. The activation of GPR120 by PUFAs or syn-
thetic ligands engages an atypical signaling system that
attenuates metabolic inflammation in obesity and type 2
diabetes [21]. A recent study has reported the beneficial
effect of a synthetic agonist of GPR120 in improving glu-
cose intolerance and hepatic steatosis in an animal
model of diet-induced obesity [22]. In addition, a num-
ber of studies have reported the potential benefits of sys-
temically targeting GPR40 in type 2 diabetes [23, 24].
A great advance in the field was achieved in 2009
when Oh and co-workers [18] described a completely
new anti-inflammatory mechanism involving the action
of PUFAs through GPR120. Upon ligand binding,
GPR120 recruits β-arrestin-2, leading to the internaliza-
tion of the receptor/regulatory protein complex. The in-
ternalized β-arrestin-2 binds to TAB1 and inhibits its
binding to TAK1, which results in the inhibition of its
activity. TAK1 is a point of convergence for TNF-α and
TLR4 signal transduction, and its inhibition impairs the
progression of the signal toward JNK and IKK activation,
which results in the inhibition of inflammation [18]. In a
recent study, the same group reported beneficial meta-
bolic effects of a small molecule that acts as a specific
agonist for GPR120 [22]. Obese mice treated with this
molecule exhibit improved glucose tolerance and de-
creased hepatic steatosis accompanied by a reduction of
the metabolic inflammation phenotype, indicating
GPR120 is an attractive potential target for the treat-
ment of obesity-associated metabolic disorders.
A number of studies have also shown the beneficial
metabolic effects of GPR40 activation [20, 25, 26]. This
receptor is highly expressed in pancreatic β-cells and,
upon activation by PUFAs, it increases glucose-induced
insulin secretion [20]. In addition, it has been shown
that GPR40 expressed in intestinal L and K cells induces
GLP1 and GIP secretion, providing yet another stimulus
for insulin secretion [27]. Although the mechanisms of
action of GPR40 are less understood than those of
GPR120, studies have shown that the induction of Ca++
mobilization and activation of CREB may play important
roles in some of the effects of this pathway [28]. Thus,
the potential therapeutic usefulness of agonists for
GPR40 is considered relevant [24].
As an attempt to advance understanding of the mech-
anisms underlying the beneficial metabolic effects of the
activation of GPR120 and GPR40, we decided to evalu-
ate their expression and function in the hypothalamus.
We show that GPR120 was predominantly expressed in
microglia, whereas GPR40 was predominantly expressed
in neurons. Furthermore, their activation reduced
obesity-associated hypothalamic inflammation and re-
duced whole-body energy efficiency.
Methods
GPR120 and GPR40 synthetic agonists
GW9508 was purchased from Tocris Bioscience (Ellis-
ville, MO, USA). TUG905 [29] and TUG1197 [30] were
synthesized as previously described.
Chemicals and reagents
All of the reagents for SDS-polyacrylamide gel electrophor-
esis and immunoblotting were from Bio-Rad (Richmond,
CA, USA). HEPES, phenylmethylsulfonyl fluoride, aprotinin,
dithiothreitol, Triton X-100, Tween 20, glycerol, and bovine
serum albumin (fraction V) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). The antibodies against
GPR120 (sc99105), GPR40 (sc32905), neuropeptide-Y (NPY)
(sc133080), proopiomelanocortin (POMC) (sc18263), Iba1
(sc28530), β-arrestin-2 (sc13140), vimentin (sc373717),
insulin-like growth factor binding protein-2 (IGFBP2)
Table 1 Macronutrient composition of diets
Chow diet HFD
Macronutrients g/100 g Kcal% g/100 g Kcal%
Protein 20 80 20 80
Carbohydrates 62 248 45 180
Lipids 4 36 35 315
Kcal/100 g 364 575
Dragano et al. Journal of Neuroinflammation  (2017) 14:91 Page 2 of 16
(sc365368), and p-IKKα/β (Thr 23) (sc21660) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The α-
tubulin (T5168) antibody was from Sigma-Aldrich (St.
Louis, MO, USA). The antibodies against mannose receptor
(ab8918) and beta-actin (ab8227) were from Abcam (Cam-
bridge, MA, USA). The reagents for chemiluminescence la-
beling of proteins in immunoblots were from Amersham
(Aylesbury, UK). Fluorescein-isothiocyanate (FITC)-conju-
gated anti-rabbit (sc2012), FITC-conjugated anti-goat
(sc2024), rhodamine-conjugated anti-rabbit (sc2091), and
rhodamine-conjugated anti-goat (sc094) antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Reagents for real-time polymerase chain reaction (PCR)
analysis were from Invitrogen (Carlsbad, CA, USA) and
Applied Biosystems (Foster City, CA, USA). Primers for
tumor necrosis factor-alpha (TNF-α) (Mm00443258_m1),
interleukin-1 beta (IL1β) (Mm00434228_m1), interleukin-6
(IL6) (Mm00446190_m1), interleukin-10 (IL10)
(Mm01288386_m1), GPR120 (Mm00726193_m1), GPR40
(Mm00809442_s1), peroxisome proliferator activator
gamma coactivator 1 alpha (PGC1α) (Mm00447183_m1),
uncoupling protein-1 (UCP1) (Mm01244861_m1), cyto-
chrome c (Mm01621044_g1), and glyceraldehyde-3-
phosphate dehydrogenase (GAPD) (#4352339E) were ob-
tained from Applied Biosystems.
Experimental animals
Male Swiss mice originally imported from the Jackson
Laboratory and currently bred at the University of Cam-
pinas Breeding Center were used in the study. The ani-
mals were maintained at 21 ± 3 °C on a 12-h artificial
light/dark cycle and were housed in individual cages. At
the fifth week of life, mice were randomly assigned to ei-
ther a standard rodent chow diet (Chow) or high-fat diet
(HFD, 60% of energy value from fat, Table 1, at the end
of the document text file.) for 4 weeks or 10 weeks, de-
pending on the protocol.
Fig. 1 Cellular distribution of GPR120 in the hypothalamus of mice. Tissue sections (5.0 μm) were prepared from the hypothalamic region of lean
Swiss mice and were evaluated by indirect immunofluorescence staining using antibodies against GPR120 (a–c, green), NPY (a, red), POMC (b, red), and
mannose receptor (c, red). Nuclei were stained with DAPI (blue). In the captions, the arrows indicate cells co-expressing GPR120 and mannose receptor
(c). Images are representative of three independent experiments
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Experimental protocols
For the evaluation of GPR120 and GPR40 expression in
the white adipose tissue, liver, intestine, frontal cortex,
occipital cortex, hippocampus, and hypothalamus, mice
were fed for 9 weeks on chow and then employed for
RNA extraction. To assess GPR120 signal transduction,
mice fed a HFD for 4 weeks were anesthetized and sub-
jected to acute lateral ventricle hypothalamic microinjec-
tion of 2.0 μL of vehicle or GW9508 (1.0 mM), using a
Stoelting stereotaxic apparatus set on the following coor-
dinates: anteroposterior, 0.34 mm; lateral, 1.0 mm; and
depth, 2.2 mm. After 90 min, the hypothalamus was re-
moved, and protein or RNA extracts were utilized in im-
munoprecipitation and western blot experiments or real-
time PCR analysis, respectively. In another set of experi-
ments, mice were randomly assigned to chow or a HFD
for 4 weeks; subsequently, mice were positioned in a
Stoelting stereotaxic apparatus to place a cannula in the
lateral ventricle using the stereotaxic coordinates
described above. Correct positioning of the cannula was
tested 5 days after cannulation by evaluation of the thirst
response elicited by intracerebroventricular (icv) angio-
tensin II (10−6 M). Icv-cannulated mice were treated
twice a day for 6 days with 2.0 μL of vehicle, GW9508
(1.0 mM), TUG1197 (1.0 mM), or TUG905 (1.0 mM).
Treatments were administered at 8 am and 5 pm. Food
intake and body mass were measured during the treat-
ment period. In each group, some mice were randomly
selected for indirect calorimetry and spontaneous phys-
ical activity measurements. At the end of the experi-
ment, the hypothalamus was collected for real-time PCR
analysis.
Cell culture
The neuronal cell line mHypoA 2/29 CLU189 (CLU189)
and the microglial cell line BV2 were cultivated to 70%
confluence in Dulbecco’s modified Eagle’s medium
(DMEM) containing 25 mM glucose and 10% fetal
Fig. 2 Cellular distribution of GPR40 in the hypothalamus of mice. Tissue sections (5.0 μm) were prepared from the hypothalamic region of lean
Swiss mice and were evaluated by indirect immunofluorescence staining using antibodies against GPR40 (a–c, green), NPY (a, red), POMC (b, red),
and Iba1 (c, red). Nuclei were stained with DAPI (blue). In the captions, the arrows indicate cells co-expressing GPR40 and NPY (a), and GPR40 and
POMC (b). Images are representative of three independent experiments
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bovine serum. Both cell lines were treated with GW9508
(100 μM), TUG1197 (100 μM), and TUG905 (100 μM)
for 1 h prior to lipopolysaccharide (LPS) (100 ng/mL)
treatment for 10 min and then subjected to western blot
analysis. The doses of the agonists were selected follow-
ing a dose response experiment.
Lentivirus efficiency
Five commercially available shRNA-encoding lentivirus
plasmids to GPR120: LV1 (NM_181748 1-123s1c1), LV2
(NM_181748 1-816s1c1), LV3 (NM_181748 1-852s1c1),
LV4 (NM_181748 1-1105s1c1), and LV5 (NM_181748 1-
1253s1c1), and a scrambled shRNA control plasmid
(SHC016V 11051235 MN) (Sigma-Aldrich) were tested in
the CLU189 cell line to determine the effectiveness of each
shRNA-mediated GPR120 knockdown. GPR120 silencing
was evaluated in cell lysates by western blot analysis.
Hypothalamic lentivirus delivery
Hypothalamic delivery of the lentivirus was performed
in Swiss mice after 4 weeks on a HFD. Mice were placed
in a Stoelting stereotaxic apparatus for bilateral hypo-
thalamic injection of 1.0 μL of lentivirus using a
Hamilton syringe linked to a 30-gauge needle. The coor-
dinates were adjusted to target the arcuate nucleus as
follows: anteroposterior, −1.7 mm; lateral, 0.3 mm;
dorsoventral, −5.5 mm. After the lentivirus infection,
body mass and food intake were recorded over 10 weeks.
In the eigth and ninth experimental weeks, the animals
were subjected to an intraperitoneal glucose tolerance
test and an intraperitoneal insulin tolerance test. At the
end of the tenth experimental week, a cannula was
placed in the lateral ventricle (as previously described),
and the mice were treated twice a day for 6 days with
2.0 μL of vehicle or GW9508 (1.0 mM). Finally, the
hypothalamus was collected for analysis.
Intraperitoneal glucose tolerance test (ipGTT) and insulin
tolerance test (ipITT)
An Intraperitoneal glucose tolerance test (ipGTT)and an
insulin tolerance test (ipITT) were performed on food-
deprived (6 h) non-anesthetized mice. Blood glucose
levels were measured with an OptiumTM mini (Abbott
Diabetes Care, Alameda, CA, USA) handheld gluc-
ometer using appropriate test strips. For the ipGTT, a
solution of 20% glucose (2.0 g/kg body weight) was ad-
ministered into the peritoneal cavity. Blood samples
were collected from the tail vein at 30, 60, 90, and
120 min post-glucose administration for the determin-
ation of glucose concentrations. The area under the
Fig. 3 Cellular distribution of GPR120 in the hypothalamus of mice. Tissue sections (5.0 μm) were prepared from the hypothalamic region of lean
Swiss mice and were evaluated by indirect immunofluorescence staining using antibodies against GPR120 (a–b, red in A and green in B), vimentin
(a, green), and IGFBP2 (b, red). Nuclei were stained with DAPI (blue). In the captions, the yellow circle indicates region with cells co-expressing
GPR120 and vimentin (a). Images are representative of three independent experiments
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curve (AUC) was calculated using these values. For the
ipITT, glucose blood levels were sampled 5, 10, 15, 20,
25, and 30 min following the intraperitoneal injection of
insulin (0.75 U/kg). The rate constant for glucose dis-
appearance during the insulin tolerance test (Kitt) was
calculated using the formula 0.693/t1/2. The t1/2 for
glucose was calculated from the slope of the least-
squares analysis of the plasma glucose concentrations
during the linear decay phase [31].
Western blot and immunoprecipitation
Hypothalamic specimens were homogenized, and samples
containing 75–100 mg protein were used as a whole-
tissue extract in western blot experiments, as previously
described [31]. The proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) transferred to nitrocellulose membranes and blot-
ted with the antibodies indicated, as described in the Re-
sults. Specific bands were labeled by chemiluminescence
and were quantified by optical densitometry. For immuno-
precipitation, hypothalamic lysates (500 μg protein con-
tent) were incubated with 1 mg of anti-β-arrestin-2
antibody overnight at 4 °C, and immune complexes were
precipitated with Protein A for 6 h. The samples were
then washed with phosphate-buffered solution and were
resuspended in sample buffer. Immune complexes were
separated by SDS-PAGE, and membranes were blotted
with either GPR120 or β-arrestin-2 antibodies.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using the commercially avail-
able acid-phenol reagent Trizol (Invitrogen Corp.). RNA
Fig. 4 Expression and activation of GPR120 and GPR40. The expression of GPR120 (a and c) and GPR40 (b and d) transcripts were evaluated by
real-time PCR in samples collected from the small intestine, liver, white adipose tissue (WAT), frontal cortex, occipital cortex, hippocampus, and
hypothalamus (a and b) of lean Swiss mice or in samples prepared from the mHypoA 2/29 CLU189 and BV2 cell lines (c and d). In e–g, lean Swiss
mice were subjected to intracerebroventricular cannulation and treated with a single dose of GW9508 (2.0 μl, 1.0 mM); samples were collected
after 90 min for the evaluation of GPR120 (E) or GPR40 (g) transcript expression by real-time PCR. In addition, protein samples were utilized in
immunoprecipitation experiments using an anti-β-arrestin-2 antibody; immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose
membranes, and immunoblotted (IB) with GPR120 or β-arrestin-2 antibodies (f). In all experiments, n = 5. In C and D, *p < 0.05 vs. CLU189; in E and F,
*p < 0.05 vs. vehicle
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concentration, purity, and integrity were confirmed
spectrophotometrically using a Nanodrop (ND-1000;
Nanodrop Technologies, Wilmington, DE). The first-
strand cDNA was synthesized using SuperScript III re-
verse transcriptase and random hexamer primers as de-
scribed in the manufacturer’s protocol (Invitrogen
Corp.). Quantitative PCR was run to determine the ex-
pression of TNF-α, IL1β, IL6, IL10, POMC, and NPY in
the hypothalamus and to determine the expression of
PGC1α, UCP1 and cytochrome c in the brown adipose
tissue using primers supplied with commercially avail-
able assays from Applied Biosystems. The reference gene
was GAPD. Real-time PCR analysis of gene expression
was carried out in an ABI Prism 7500 sequence detec-
tion system (Applied Biosystems). For each gene, the op-
timal concentration of complementary DNA and
primers as well as the maximum efficiency of amplifica-
tion were obtained through 5-point, twofold dilution
curve analysis. Amplification was performed in a 20-μL
final volume containing 40–50 ng of reverse-transcribed
RNA according to the manufacturer’s recommendations
using the TaqMan PCR master mix. Real-time data were
analyzed using the Sequence Detector System 1.7 (Ap-
plied Biosystems). The results are expressed as relative
transcript amounts, as previously optimized [32].
Immunofluorescence staining
For histological analysis, deep-frozen hypothalamic tis-
sue samples were employed in coronal sectioning
(5.0 μm). Specimens were double-labeled with either
anti-GPR120 or anti-GPR40 antibodies and specific pri-
mary antibodies against markers related to the different
cell types, including NPY, POMC, Iba1, mannose recep-
tor, vimentin, and IGFBP2. Thereafter, the sections were
incubated with specific FITC- or rhodamine-conjugated
IgG secondary antibodies and DAPI for nuclear staining.
Immunofluorescence imaging was performed to evaluate
the distribution of GPR120 and GPR40 in the hypothal-
amus of the mice. The specificity of the antibodies
against GPR120 and GPR40 was evaluated in a separate
set of experiments (Additional file 1: Figure S1).
Indirect calorimetry and spontaneous physical activity
Oxygen consumption/carbon dioxide production and
spontaneous physical activity were measured in fed
animals using a computer-controlled, open-circuit calor-
imeter system (LE405 gas analyzer; Panlab-Harvard Ap-
paratus). Mice were single-housed in clear respiratory
chambers, and room air passed through the chambers at
a flow rate of ten times the body weight of each animal.
The air-flow within each chamber was monitored by a
sensor (Air Supply and Switching; Panlab-Harvard Ap-
paratus). Gas sensors were calibrated prior to the onset
of experiments with primary gas standards containing
known concentrations of O2, CO2, and N2 (Air Liquid).
The analyses were performed over a 24-h period. Out-
door air reference values were sampled after every four
measurements. Sample air was sequentially passed
through O2 and CO2 sensors for the determination of
O2 and CO2 content, from which the measures of oxy-
gen consumption (VO2) and carbon dioxide production
(VCO2) were estimated. The VO2 and VCO2 were calcu-
lated by Metabolism version 2.2 software based on the
Withers equation and are expressed in milliliters per
hour-1 per gram-1. The respiratory quotient was calcu-
lated as VCO2/VO2. Energy expenditure was estimated
as VO2/body mass (grams) [33].
Statistical analysis
All results are reported as the mean ± SEM. Differences
between the treatment groups were evaluated using an
unpaired Student’s t test or a one-way analysis of vari-
ance (ANOVA). When the ANOVA indicated signifi-
cance, a Tukey-Kramer post-hoc test was performed
(GraphPad Software, San Diego, CA, USA). A p < 0.05
was accepted as statistically significant.
Results
The expression of GPR120 and GPR40 in the
hypothalamus of mice
The expression and cellular localization of GPR120 and
GPR40 were evaluated in the hypothalamus of male, lean
Swiss mice by indirect immunofluorescence staining. As
depicted in Fig. 1a–c, the majority of the cells that
expressed the microglia marker, mannose receptor, also
expressed GPR120 (Fig. 1c). Conversely, we detected no
co-localization of GPR120 with either NPY (Fig. 1a) or
POMC (Fig. 1b). Figure 2a–c shows that the majority of
the cells that expressed NPY (Fig. 2a) and POMC
(Fig. 2b) also expressed GPR40, whereas the majority of
(See figure on previous page.)
Fig. 5 Intracerebroventricular treatment with GW9508 in lean mice. Five-week-old Swiss mice were included in the study and were fed on chow for
4 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either vehicle (2.0 μl) or GW9508 (2.0 μl,
1.0 mM) icv treatment twice a day for 6 days (a). Body mass (b and c) and caloric intake (d) were measured during the experimental period. At the
end of the experimental period, some mice were subjected to indirect calorimetry and the determination of spontaneous physical activity, resulting in
the values for O2 consumption (E–F), CO2 production (g–h), energy expenditure (i–j), respiratory quotient (k), and spontaneous physical activity (l). At
the end of the experimental period, the hypothalamus was dissected, and RNA was extracted for real-time PCR determination of transcript levels of
TNF-α (m), IL1β (n), IL10 (o), and IL6 (p). In all experiments, n = 5; *p < 0.05 vs. vehicle
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the cells that expressed the microglia marker, Iba1, did
not express GPR40 (Fig. 2c). Because of the localization
and shape of GPR120-expressing cells (as depicted in
Fig. 1) were similar to that described for tanycytes
present in the periventricular area [34, 35], we evaluated
the potential co-expression of GPR120 with vimentin
(Fig. 3a), a general marker of tanycytes, and IGFBP2
(Fig. 3b), a specific marker for β1-tanycytes [34, 35].
There was only a minor co-localization of GPR120 and
vimentin in the region of the junction between the
medium eminence and the arcuate nucleus (Fig. 3a).
However, no co-localization was observed between
GPR120 and IGFBP2 (Fig. 3c). Next, the relative tran-
script amounts of both GPR120 and GPR40 were evalu-
ated by real-time PCR in samples from distinct tissues of
the body. As depicted in Fig. 4a, GPR120 was predomin-
antly expressed in the intestine and white adipose tissue,
whereas its levels were low in the central nervous system
and similar across the regions tested: frontal cortex, oc-
cipital cortex, hippocampus, and hypothalamus. Con-
versely, the transcript levels of GPR40 (Fig. 4b) were as
high in the hypothalamus as in the intestine, liver, and
adipose tissue, whereas in the other brain regions tested,
its expression was considerably lower. Finally, we evalu-
ated the expressions of GPR120 (Fig. 4c) and GPR40
(Fig. 4d) transcripts in a hypothalamic neuronal cell line,
CLU189 [36], and in a microglial cell line, BV2 [37].
Consistent with the findings in the mice, CLU189 cells
expressed higher relative amounts of GPR40 compared
to GPR120, whereas the opposite occurred in BV2 cells.
The activation of hypothalamic GPR120 and GPR40 in
lean mice
GW9508 is a synthetic agonist that activates GPR120
and GPR40 with EC50 values of 2.2 μM and 47 nM, re-
spectively [26]. Upon hypothalamic delivery, GW9508
was not capable of changing GPR120 transcript expres-
sion (Fig. 4e) but promoted its activation through the
engagement of β-arrestin-2 (Fig. 4f ). In addition,
GW9508 stimulated an increase of GPR40 transcript
levels (Fig. 4g). Next, we treated lean mice with two daily
doses of GW9508-delivered icv for 6 days (Fig. 5a). The
treatment did not cause a significant change in body
mass (Fig. 5b, c) or in spontaneous caloric intake
(Fig. 5d). However, mice treated with the compound ex-
hibited significantly increased O2 consumption (Fig. 5e,
f ) and CO2 production (Fig. 5g, h), resulting in increased
energy expenditure (Fig. 5i, j) in the absence of any
modifications of RQ (Fig. 5k) or spontaneous physical
activity (Fig. 5l). Interestingly, icv GW9508 induced a re-
duction of the hypothalamic expression of IL1β (Fig. 5n)
and an increase of IL10 (Fig. 5o), without causing a
change in TNF-α (Fig. 5m) or IL6 (Fig. 5p).
The activation of GPR120 and GPR40 in obese mice
Male Swiss mice were fed on a HFD for 4 weeks and
then subjected to icv cannulation for treatment with
GW9508 twice a day for 6 days (Fig. 6a). GW9508 pro-
duced no change in body mass (Fig. 6b, c) but increased
caloric intake (Fig. 6d), resulting in reduced energy effi-
ciency (Fig. 6e). These changes were not accompanied
by modifications of O2 consumption (Fig. 6f ), CO2 pro-
duction (Fig. 6g), energy expenditure (Fig. 6h), or spon-
taneous physical activity (Fig. 6i). However, RQ was
reduced (Fig. 6j), and there were trends toward increased
expression of UCP1 (Fig. 6k), PGC1α (Fig. 6l), and cyto-
chrome c (Fig. 6m) in the brown adipose tissue. More-
over, GW9508 reduced hypothalamic TNF-α (Fig. 6n)
and IL1β (Fig. 6o), accompanied by increased IL10
(Fig. 6p) without a change in IL6 (Fig. 6q).
Lentiviral targeting of GPR120 in obese mice
Lentiviruses harboring five different shRNA sequences
were employed in an attempt to inhibit the expression of
GPR120. As depicted in Fig. 7a, lentiviruses 1 and 2
(LV1 and LV2) were the most effective in reducing
GPR120 expression in CLU189 cells. Bilateral injections
of either LV1 or LV2 into the arcuate nucleus (Fig. 7b)
resulted in the reduction of GPR120 expression (Fig. 7c).
Obese mice were then treated with LV1 via bilateral in-
jection into the arcuate nucleus and followed up for
10 weeks before undergoing icv cannulation for treat-
ment with GW9508 for 6 days (Fig. 7d). During the
10 weeks before GW9508 treatment, mice injected with
LV1 presented no changes in body mass (Fig. 7e, f ) or
caloric intake (Fig. 7g). Glucose and insulin tolerance
tests were performed but revealed no differences be-
tween the groups (data not shown). Following GW9508
(See figure on previous page.)
Fig. 6 Intracerebroventricular treatment with GW9508 in obese mice. Five-week-old Swiss mice were included in the study and were fed on a high-fat diet
(HFD) for 4 weeks before intracerebroventricular (icv) cannulation; after 1 week, mice were randomly selected for either vehicle (2.0 μl) or GW9508 (2.0 μl,
1.0 mM) icv treatment twice a day for 6 days (a). Body mass (b and c), caloric intake (d), and energy efficiency (e) were measured during the experimental
period. At the end of the experimental period, some of the mice were subjected to indirect calorimetry and the determination of spontaneous physical
activity, resulting in the values for O2 consumption (F), CO2 production (g), energy expenditure (h), spontaneous physical activity (i), and respiratory quotient
(j). RNA samples were obtained from the brown adipose tissue for real-time PCR determination of the transcript expression of UCP1 (k), PGC1α (l), and
cytochrome c (m). In addition, the hypothalamus was dissected, and RNA was extracted for real-time PCR determination of the transcript levels of TNF-α
(n), IL1β (o), IL10 (p), and IL6 (q). In all experiments, n= 5; *p< 0.05 vs. vehicle
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treatment, there was no change in body mass (Fig. 7h),
but caloric intake was reduced (Fig. 7i), resulting in higher
energy efficiency (Fig. 7j). In addition, the hypothalamic
expression of IL10 was significantly reduced (Fig. 7k).
The use of specific synthetic agonists of GPR120 and
GPR40 in obese mice
In the last part of the study, we employed two synthetic
agonists recently developed to specifically activate either
GPR120 or GPR40. TUG1197 activates only GPR120,
with a pEC50 of 6.32 (inactive on GPR40), whereas
TUG905 activates only GPR40, with a pEC50 of 7.03 (in-
active on GPR120) [38]. The capacity of either com-
pound to reduce LPS-induced activation of IKK was
determined in CLU189 (Additional file 1: Figure S2A)
and BV2 (Additional file 1: Figure S2B) cells in parallel
with GW9508. As shown in Additional file 1: Figure S2A
and B, TUG905 was effective in reducing IKK activity in
either cell type, whereas TUG1197 was capable of redu-
cing IKK activity only in BV2 cells. GW9508 treatment
resulted in a trend to reduce the activation of IKK in
BV2 (p = 0.07) but not in CLU189, probably because of
the low expression of GPR120 in this cell line. Next,
obese mice were treated icv with either compound for
6 days (Additional file 1: Figure S2C). TUG1197 had no
effect on body mass (Additional file 1: Figure S2D) and
caloric intake (Additional file 1: Figure S2E); however, it
exerted potent anti-inflammatory activity, reducing TNF-α
(Additional file 1: Figure S2F) and IL1β (Additional file 1:
Figure S2G) while increasing IL10 (Additional file 1:
Figure S2H) and IL6 (Additional file 1: Figure S2I) in
the hypothalamus. TUG1197 had no significant effect on
the expression of NPY (Additional file 1: Figure S2J)
and POMC (Additional file 1: Figure S2K). Conversely,
TUG905 reduced body mass (Additional file 1: Figure S2D)
and exhibited a trend toward reducing caloric intake
(Additional file 1: Figure S2E). TUG905 had no effect
on TNF-α (Additional file 1: Figure S2F) and IL1β
(Additional file 1: Figure S2G) but induced an in-
crease of IL10 (Additional file 1: Figure S2H) and IL6
(Additional file 1: Figure S2I) in the hypothalamus. In
addition, TUG905 had no effect on the transcript
levels of NPY (Additional file 1: Figure S2J) but in-
creased POMC (Additional file 1: Figure S2K).
Discussion
The beneficial effects of dietary PUFAs were first re-
ported in epidemiological studies showing that Inuit and
Mediterranean populations are protected from cardio-
vascular disease due to the consumption of fish and
olive oil, which are rich in ω3 and ω9 PUFAs, respect-
ively [39–41]. Mechanistic studies performed during the
last 40 years have shown that at least a portion of the
favorable metabolic effects of PUFAs is due to their
anti-inflammatory actions. There are different anti-
inflammatory pathways that can be induced by PUFAs.
ω3 fatty acids can compete with arachidonate for 5-LOX
and COX2, which catalyze the synthesis of eicosanoids
[42, 43]. Variations in the rates of ω3 and ω6 availability
can shift the amounts of the final products of this syn-
thetic pathway [44]. When ω6 predominates, pro-
inflammatory prostaglandins, leukotrienes, prostacyclins,
and thromboxanes are produced [44, 45]. Conversely,
upon preferential ω3 availability, the resulting eicosa-
noids, including protectins, resolvins, and lipoxins, are
either less pro-inflammatory or are anti-inflammatory
[44–46]. Transcriptional regulation is yet another mech-
anism underlying the anti-inflammatory actions of
PUFAs [47]. DHA can activate PPARγ, leading to the in-
hibition of inflammatory gene expression [48]. In
addition, PPARγ can also inhibit NFκB activity by indu-
cing the expression of IκBα [49].
More recently, new anti-inflammatory mechanisms
have been attributed to PUFAs. These findings emerged
mostly due to the work exploring the properties of the
previously orphan receptors, GPR120, and GPR40 [20, 25].
Because of the potential use of agonists for these receptors
as therapeutic tools for metabolic diseases, we decided
to evaluate their presence and action in the hypothalamus
of obese rodents.
(See figure on previous page.)
Fig. 7 Lentiviral targeting of GPR120. In a, the mHypoA 2/29 CLU189 cell line was transfected with lentivirus containing five distinct (LV1–LV5)
sequences of shRNA targeting GPR120 and, in addition, a scrambled control. Protein extracts were prepared and subjected to separation by SDS-
PAGE, then transferred to a nitrocellulose membrane and blotted with anti-GPR120 antibody. The sequences LV1 and LV2 were utilized in in vivo
experiments and were injected bilaterally into the arcuate nucleus (b). 7 days after LV1 or LV2 injection, hypothalami were dissected and used for
protein extraction. Samples were subjected to separation by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted (IB) with an
antibody against GPR120 (c). Swiss mice were fed for 4 weeks on a high-fat diet (HFD) and then injected with LV1 or the scrambled control
construct into the arcuate nucleus bilaterally; after 10 weeks, the mice were subjected to intracerebroventricular cannulation and following a
recovery period of 7 days, subjected to treatment with GW9508 (2.0 μl, 1.0 mM) twice a day for 6 days (d). Body mass (e and f) and caloric intake
(g) were determined during the 10 weeks that followed LV1/scramble injection (before GW9508 treatment). Body mass (h), caloric intake (i), and
energy efficiency (j) were evaluated during the 6 days that followed GW9508 treatment. At the end of the experimental period, IL10 protein
expression was determined in extracts from the hypothalamus (k). In c and k, loading controls were obtained by reprobing the membranes with
anti-α-tubulin antibody. In A, the results are representative of three independent experiments. In C, n = 4; *p < 0.05 vs. scramble. In E–K, n = 5; *p < 0.05
vs. scramble
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Studies have shown that the consumption of dietary
fats, particularly long-chain saturated fatty acids, induces
the activation of site-specific inflammation in the hypo-
thalamus [32, 50–54]. At least three distinct mechanisms
seem to be involved in the activation of the inflamma-
tory response: TLR4 activation, PKC-theta activation
and ERS [32, 50–55]. Pharmacological and genetic ap-
proaches used to dampen the inflammation mediated by
each of these mechanisms have produced encouraging
results with respect to the control of body adiposity and
whole-body metabolism [32, 50–55]. Previously, we have
shown that PUFAs in the diet or injected directly into
the hypothalamus can reduce hypothalamic inflamma-
tion and can improve the metabolic phenotype [19]. In
addition, PUFAs can induce hypothalamic neurogenesis
of predominantly POMC neurons [56]. With these re-
sults in mind, we hypothesized that at least a portion of
the effects of PUFAs in the hypothalamus could be me-
diated by GPR120 and GPR40.
Accordingly, in the first part of the study, we showed
that both receptors are expressed in the hypothalamus.
GPR40 levels were considerably higher than GPR120
levels and were similar to the levels expressed in periph-
eral tissues, such as adipose tissue, intestine, and the
liver. Previous studies have reported the presence of high
levels of GPR40 in the brain [25]; however, the majority
of the work has been focused on the characterization of
its role in hippocampal neurogenesis [28, 57]. There is
one previous study showing that GPR40 is present in
neurons of the hypothalamus, but the type of neuron
was not explored [58]. The study showed an
involvement of hypothalamic GPR40 in the response to
inflammatory chronic pain [58]. In addition, we showed
that inhibiting hypothalamic GPR40 reduces PUFA-
induced neurogenesis [56]. Here, we confirmed that
GPR40 is present predominantly in hypothalamic neu-
rons, and we expanded this characterization by demon-
strating that both NPY and POMC neurons express the
highest levels of this receptor.
Regarding GPR120, we showed that it is also present
in the hypothalamus; however, the levels of transcript
were much lower than in peripheral tissues involved in
metabolic activity, such as intestine and adipose tissue
[59]. Nevertheless, the levels in the hypothalamus were
not that different from the levels in other regions of the
brain. The fact that most hypothalamic GPR120 is
expressed in microglia may explain why the expression
levels were in general quite low. One interesting aspect
of the immunofluorescence studies used to characterize
the cellular distribution of GPR120 is the fact that some
cells expressing GPR120 in the periventricular region
nearby the interface between the medium eminence and
the arcuate nucleus presented projections in a shape
very similar to tanycytes [34, 35]. Because of that, we
performed staining with vimentin, which is expressed in
different types of tanycytes and IGFBP2, which is
expressed in β1-tanycytes. Our results showed only a
limited co-localization of GPR120 with vimentin, and, as
compared with the staining for mannose receptor, we
can conclude that most of GPR120 is expressed in
microglia. Our group has published the only previous
study reporting the presence of GPR120 in the
Fig. 8 Schematic representation of the main findings of this study. GPR120 and GPR40 are expressed in the hypothalamus of mice; GPR120 is
expressed predominantly in microglia whereas GPR40 is expressed predominantly in POMC and NPY neurons. The intracerebroventricular (icv)
injection of agonists in mice results in a number of phenotypic changes. TUG1197, the GPR120 agonist, acts predominantly reducing
hypothalamic inflammation. TUG905, the GPR40 agonist, acts predominantly reducing body mass and increasing the expression of the
anorexigenic precursor, POMC. The use of a compound that acts simultaneously on GPR120 and GPR40, GW9508, results in the best metabolic
outcomes, reducing body mass, improving glucose tolerance and reducing hypothalamic inflammation
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hypothalamus; however, in that study, we did not ex-
plore its cellular distribution or its functional relevance
[19]. Another study has shown that GPR120 is expressed
in a hypothalamic neuronal cell line and can control in-
flammation [60].
We initially used a non-specific agonist, GW9508, to
evaluate the impact of combined GPR120/GPR40 activation
in the hypothalamus. There were few differences in the final
outcomes of GW9508 treatment when comparing lean ver-
sus obese mice, but as a rule, there were improvements in
both inflammatory and metabolic parameters. The impact
on the regulation of body mass was not as impressive as
the effects obtained when other anti-inflammatory ap-
proaches are used to dampen obesity-induced hypothal-
amic inflammation, such as the inhibition of JNK [50], IKK
[54], TLR4 [51], or ERS [52]. In fact, the mild effect ob-
tained with the use of GW9508 is consistent with the fact
that reducing GPR120 expression with lentivirus-delivered
shRNA also resulted in mild phenotypic changes.
As an attempt to define the specific actions of GPR120
and GPR40 in the hypothalamus, we employed two re-
cently developed compounds that exhibit no cross-
activity between these receptors. TUG905 acts on
GPR40 only, and upon icv treatment, it produced
changes predominantly in energy homeostasis, reducing
body mass even in the absence of changes in caloric in-
take. Interestingly, TUG905 increased the levels of
POMC without changing the expression of NPY. At first,
this could seem unexpected because the majority of the
expression of GPR40 in the hypothalamus is found in
NPY neurons; however, it has been shown that NPY
neurons can modulate POMC production through a
plastic connectivity system [61–63].
Conversely, the action of TUG1197 on GPR120 pro-
duced no change in caloric intake and body mass but re-
duced hypothalamic inflammation. Considering that
reductions of body adiposity have been observed in
other studies that used approaches that acted solely on
the inflammatory aspect of the hypothalamic dysfunc-
tion in obesity [32, 50–54], one could ask why this did
not happen with TUG1197. In our opinion, there are
two possibilities: either (i) the magnitude of the anti-
inflammatory effect was not sufficient to modify energy
homeostasis; or (ii) 6 days of treatment was not suffi-
cient to observe the putative ongoing changes in the
control of energy homeostasis.
Regardless of the answer, we conclude that both
GPR120 and GPR40 are expressed in the hypothalamus,
and the combined activation of both receptors results in
benefits for the control of whole-body energy homeosta-
sis and hypothalamic inflammation. We propose that at
least a portion of the metabolic benefits obtained with
the consumption of PUFAs may be due to the activation
of hypothalamic receptors.
Conclusions
We show that both receptors are expressed in the hypo-
thalamus; GPR120 is primarily present in microglia,
whereas GPR40 is expressed in neurons. We conclude
that GPR120 and GPR40 act in concert in the hypothal-
amus to reduce energy efficiency and to regulate the in-
flammation associated with obesity. The combined
activation of both receptors in the hypothalamus results
in better metabolic outcomes than the isolated activation
of either receptor alone. Figure 8 presents a schematic
view of the main findings of this study.
Additional file
Additional file 1: Figure S1. Testing the specificity of the antibodies
against GPR120 and GPR40. Figure S2 specific activation of GPR120 and
GPR40. (PDF 10063 kb)
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